hepatitis b vaccine (Rx) - Engerix B, Recombivax HB

 
 
 

Adult Dosing & Uses

Dosing Forms & Strengths

adult vaccine

  • 20mcg HbsAg/mL

peds vaccine

  • 10mcg/0.5mL

Hepatitis B vaccination

3 dose series

Engerix B (20+ yo)

  • 1 mL (20 mcg) IM deltoid at 0, 1, 6 months
  • Hemodialysis: 2 mL (40 mcg) at 0, 1, 2, 6 months
  • For alternate dosing schedule, see package insert

Recombivax HB (20+ yo)

  • 1 mL (10 mcg) IM deltoid at 0, 1, 6 months
  • Hemodialysis: 1 mL dialysis vacc (40 mcg) at 0, 1, 6 months

Patients with diabetes mellitus

  • CDC ACIP guidelines recommends immunization with hepatitis B vaccine for all unvaccinated adults with diabetes mellitus through age 59 years
  • Persons with diabetes are at increased risk of hepatitis B infection
  • Vaccination for older unvaccinated diabetic patients may be done at the physician's discretion MMWR Dec 23, 2011/Vol 60(50);1709-11

Administration

Do not give IV/intradermal

Consider booster dose PRN

Other Indications & Uses

Routine immunization against hepatitis B; also protects against hepatitis D which always occurs in the presence of hep B

Infants born to HbsAg+ mothers

Persons with or exposed to:

  • chronic liver & end stage renal disease, incl hemodialysis; STDs; HIV infection
  • occupational hazards, incl blood or other infectious body fluids
  • behavioural risks, incl multiple sex partners, IV drug use
  • individuals with chronic hepatitis B & in settings where Hepatitis B vaccination is recommended
  • adults diagnosed with diabetes mellitus

Adults receiving hemodialysis and/or immunocompromised adults

Also reduces risk of hepatocellular carcinoma

Additional Information

Up-to-date vaccination schedules available at www.cdc.gov/nip/publications

Next

Pediatric Dosing & Uses

Dosing Forms & Strengths

adult vaccine

  • 20mcg HbsAg/mL

peds vaccine

  • 10mcg/0.5mL

Hepatitis B vaccination

Engerix B (0-19 yo)

  • 0.5 mL peds vacc (10 mcg) IM: 0, 1, 6 mth
  • For alternate dosing schedule, see package insert

Recombivax HB (0-19 yo)

  • 0.5 mL peds vacc (5 mcg) IM: 0, 1, 6 mth
  • For alternate dosing schedule, see package insert

Administration

Deltoid for adolescents, anterolateral thigh preferred for neonates/infants/small children

Do not give IV/intradermal

Consider booster dose PRN

Previous
Next

Drug Interactions

Interaction Checker

hepatitis b vaccine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Pain (10-29%)

            Pruritus (10-29%)

            Erythema (10-29%)

            Burning (10-29%)

            Nodules (10-29%)

            Fatigue (15%)

            Headache (15%)

            Fever (15%)

            Vertigo (15%)

            1-10%

            Lightheadedness

            Flushinig

            Insomnia

            Irritability

            Arthralgia

            Constipation

            Pruritus

            Lupus-like syndrome

            Lymphadenopathy

            Tachycardia

            Previous
            Next

            Contraindications & Cautions

            Contraindications

            Hypersensitivity to yeast

            Cautions

            Not protective against hepatitis A, C, or E

            Gluteal muscle not recommended

            Heptavax B (plasma-derived) no longer used in the US

            Previous
            Next
            View Category Definitions

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: not known if excreted in breast milk

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            Previous
            Next

            Pharmacology

            Mechanism of Action

            Hepatitis B surface antigen (HBsAg) which stimulates active immunity

            Duration: not established

            Excretion: not established

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Previous
            Next

            Pricing & Images

            Previous
            Next
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
            This website also contains material copyrighted by 3rd parties.

            DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.